中国药房2017，Vol.28Issue(32)：4470-4474,5.DOI:10.6039/j.issn.1001-0408.2017.32.02
伊伐布雷定治疗我国慢性心力衰竭患者的成本-效用分析
Cost-utility Analysis of Ivabradine in the Treatment of Chronic Heart Failure in China
摘要
Abstract
OBJECTIVE:To evaluate the cost and utility of ivabradine in the treatment of chronic heart failure (CHF) patients in China.METHODS:The cost and utility of standard plan plus ivabradine (called "ivabradine plan" for short) vs.standard plan were evaluated by Markov model,and lifetime total costs and quality adjusted life years (QALYs) were obtained.The clinical parameters were obtained from SHIFT China subgroup study;cost and utility data related to CHF came from domestic published literatures.Single-factor sensitivity analysis and probability sensitivity analysis were performed to test cost-utility analysis.RESULTS:Compared with standard plan,ivabradine plan could increase 0.30 QALYs;at the same time,the total cost increased by 20 153.70 yuan,and the incremental cost-utility ratio was 67 189.50 yuan/QALY.Probability sensitivity analysis showed that the probability of ivabradine plan with cost and utility was 90％ when pay threshold was 3 times GDP per capita (140 000 yuan/QALY).The cardiovascular mortality risk ratio of ivabradine plan to standard plan was most sensitive model parameters.CONCLUSIONS:Compared with standard plan,additional use of ivabradine in the therapy for China CHF patients shows cost and utility.关键词
伊伐布雷定/慢性心力衰竭/中国/成本-效用分析/药物经济学Key words
Ivabradine/Chronic heart failure/China/Cost-utility analysis/Pharmacoeconomics分类
医药卫生引用本文复制引用
付洁,吴斌,林厚文..伊伐布雷定治疗我国慢性心力衰竭患者的成本-效用分析[J].中国药房,2017,28(32):4470-4474,5.基金项目
上海市卫生计生系统重要薄弱学科建设计划项目(No.2016ZB0304) （No.2016ZB0304）
